The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma.
J. Li
No relevant relationships to disclose
S. Qin
No relevant relationships to disclose
J. Xu
No relevant relationships to disclose
W. j. Guo
No relevant relationships to disclose
J. p. Xiong
No relevant relationships to disclose
Y. Bai
No relevant relationships to disclose
G. Sun
No relevant relationships to disclose
Y. Yang
No relevant relationships to disclose
L. Wang
No relevant relationships to disclose
N. Xu
No relevant relationships to disclose
Y. Cheng
No relevant relationships to disclose
W. Zhe-Hai
No relevant relationships to disclose
L. Zheng
No relevant relationships to disclose
M. Tao
No relevant relationships to disclose